Reccomend site contains clinical guidelines and medical resources selected by experts for use by doctors, nurses and others in Ukraine Ukraine Clinical Guidance
A presentation of educational publications of the staff of the department, published during the quarantine, took place.
The monograph “Modern view on the defeat of the cardiovascular system in diabetes mellitus and methods of their correction: a focus on diabetic cardiomyopathy” by prof. L.V. Zhuravlyova, assoc. prof N.V. Sokolnikova and as. T.A. Rogachova was published
Also a tutorial for students and interns in English “Diseases of the thyroid gland” by prof. L.V. Zhuravlyova and Assoc. prof. M.V. Filonenko was published too.
On March 20, the first day of the Training Program for Doctors “ART OF TREATMENT: A POSTGRADUATE PROFESSIONAL IMPROVEMENT” was held in the on-line format through the Association’s website www.apam.org.ua.
Professor Larysa Zhuravlyova joined to the newest format of the conference and made a presentation on topic “Management of patients with coronary heart disease and diabetes.”
The American Heart Association (AHA), American College of Cardiology (ACC) and the American Society of heart failure (HFSA) on March 17 released a new joint statement calling for continued use of antagonists of the renin-angiotensin-aldosterone system (RAAS) in patients, regardless of theoretical fear that their use may worsen the results if infection COVID-19.
Recently, a similar statement was made by the European Society of Cardiology (ESC), and the European Society of hypertension, the Canadian Society of cardiovascular disease and the International Society for hypertension.
Experts say that people with cardiovascular disease are exposed to much higher risk of serious complications, including death from COVID-19, however, a recent study – the actual data do not support the need for discontinuation of ACE inhibitors or angiotensin receptor blockers (ARBs), and researchers recommend that doctors take into account all the individual needs of each patient before making any changes in appointments ACE inhibitors or ARBs.
The new coronavirus SARS-CoV-2, which causes COVID-19 infects human cells by binding to receptors APF2 and some animal studies have shown that this mechanism increases the expression APF2 heart.
In the Lancet article assumes that patients with diabetes and hypertension increased regulation APF2 of ACE inhibitors and ARBs may increase the risk of severe and fatal COVID -19.
The authors suggested that these drugs may partially contribute to more severe and deadly COVID-19 observed in people with hypertension, diabetes and cardiovascular disease.
This article received wide coverage in the media and social networks in the UK, resulting in patients treated with their doctors, and in some cases stopped medication.
Overall, the researchers recommend that the RAAS antagonists destination for those patients who are currently appointed by the following drugs for indications such as heart failure, hypertension or coronary heart disease.
However, scientists note, if patients with cardiovascular disease diagnosed COVID-19 have made individual decisions on treatment according to the hemodynamic status of each patient and the clinical picture.
To date, no evidence of harm or good. More research is needed.
There is also a theory that ACE inhibitors and ARBs may paradoxically be useful in koronavirusniy infection.
This is because APF2 converts angiotensin II to angiotensin 1-7 vazodylyatatornyy, thereby potentially providing a hypotensive effect in animal studies has been shown that both types of drugs reduce severe lung damage in some viral pneumonia.
However, there is currently no experimental or clinical data that demonstrate a positive or negative results in the background use of ACE inhibitors, ARBs, or other antagonists RAAS in COVID-19 or in patients with COVID-19 with cardiovascular disease history, treated such drugs.
American Heart Association does not recommend adding or deleting any treatment-related RAAS, other than those based on standard clinical practice.
Literary links are amended Webcardio.org
http://www.webcardio.org/chy-pryznachaty-inghibitory-apf-i-bra-kardiologhichnym–patsijentam-z-covid-19.aspx
On January 15-18, The 30th European Days of the French Society of Cardiology was held at the Palais des Congrès in Paris. Читать дальше »
On November 14, 2019, the Ukrainian Training Program for Doctors “The Art of Treating: A Postgraduate Professional Improvement Course” was held in Kharkiv. Читать дальше »
On October 15-16, a scientific and practical conference with international participation “New trends in the diagnosis and treatment of internal diseases” dedicated to the centenary of the birth of Lyubov Malaya, was held at the Kharkiv National Medical University. Читать дальше »
On September 25-27, 2019 in Kyiv, the XX Ukrainian National Congress of Cardiology was held Читать дальше »
On September 21-24, 2019 The World Congress of Gastroenterology was held in Istanbul, Turkey. Читать дальше »
A very special edition of ESC Congress, which was held together with the World Congress of Cardiology took place at Paris, France this year from 31 Aug till 04 Sep 2019. Читать дальше »
21-24 June 2019 in Mіlan, Іtaly, the 29th European meeting on hypertension and cardiovascular protection took place.
On April 11-12, 2019 a scientific and practical conference devoted to the 100-th anniversary of the birth of Academician L.T.Malaya was held at the State University “National Institute of Therapy named after. L.T.Malaya NAMNU». Читать дальше »
On March 21, 2019, the VII Congress “Prevention, Anti-aging, Ukraine” took place in Kharkov. Читать дальше »
On December 19 at the department of Internal Medicine №3 and Endocrinology a student scientific conference Читать дальше »
Sorry, this entry is only available in Ukrainian.
